Thanks for taking the time to compose this analysis. My only issue is that the company (not to mention the board) touted the importance of secondary outcomes, specifically duration. The first two secondary outcomes listed on clinical trials are duration. So what the heck? Where is the duration information and when can we expect it? Your very informative post deals primarily with time of incidence. This is understandable given the data presented. However, your post mostly (imo), glosses over the duration endpoint, which ipix considered more important than incidence. Simply pointing out that other companies failed to provide duration numbers is not satisfactory when ipix, via PRs and on clinical trials, highlighted the importance of duration.